Ocata Therapeutics

Ocata Therapeutics

Ocata Therapuetics, formerly Advanced Cell Technology, and now called Astellas Institute for Regenerative Medicine (AIRM) is a biotechnology company focused on the development of regenerative therapeutics using stem cells in ophthalmology and other disease areas.

In late 2015 when Ocata Therapeutics was acquired by Astellas Pharma, the company’s main area of focus was the development of human embryonic stem cell-derived retinal pigmented epithelial cells (RPEs) for treatment of multiple types of macular degeneration.

Ocata Therapeutics has patents on the preparation and use of hemangio-colony forming cells, erythroid cells from pluripotent stem cells, platelets from pluripotent stem cells, mesenchymal stromal cells, photoreceptor cells, RPE cells and pluripotent stem cells as well as modalities to treat degenerative diseases of the retina. Robert Lanza is named as inventor on all patents. Robert Lanza is Head of Astellas Global Regenerative Medicine and Chief Scientific Officer at the Astellas Institute for Regenerative Medicine.

Ocata Therapeutics changed its name to Astellas Institute for Regenerative Medicine (AIRM) in 2018. In a strategy to expand beyond ophthalmology and overcome the challenge of immunological rejection of transplanted cells Astellas acquired Universal Cells and will combine technologies of AIRM and Universal Cells.

Timeline

2007
Ocata Therapeutics was founded.

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Advanced Cell Technology Changes Name to Ocata Therapeutics

BusinessWire

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.